ad image

Clinical Manufacturing

1 / 2
Navigating the Complexities of Microbial and Mammalian Manufacturing
CDMO

Navigating the Complexities of Microbial and Mammalian Manufacturing

Peter Boman; Helena Pettersson

NorthX Biologics

PAO-12-24-CL-3Jan 02, 2025
Advancing the Science of Technical and Therapeutic Proteins
CDMO

Advancing the Science of Technical and Therapeutic Proteins

Eva-Karin Gidlund, Ph.D.

NorthX Biologics

PAO-11-24-CL-10Dec 04, 2024
HuidaGene Therapeutics
FDA

HuidaGene Therapeutics Receives the First-Ever FDA Clearance of CRISPR/Cas13 RNA-Editing HG202 for Macular Degeneration

HuidaGene Therapeutics

PR-10-24-NI-81Nov 07, 2024
PCI Pharma Services
Clinical Trials

PCI Pharma Services Wins Supply Chain Excellence Award for Digital Platform to Manage Clinical Trials and Commercial Lifespans

PCI Pharma Services

PR-10-24-NI-68Oct 30, 2024
Chime Biologics
Biologics

Chime Biologics and MedPacto Form Strategic Partnership to Accelerate Global Biologics Development and Manufacturing

Chime Biologics

PR-10-24-NI-66Oct 29, 2024
Johnson & Johnson
Clinical Trials

TREMFYA is the first and only IL-23 inhibitor to demonstrate robust results with regimen in both induction and maintenance

Johnson & Johnson

PR-10-24-NI-64Oct 28, 2024
A New Vision for Progressing Advanced Therapies
Advanced Therapies

A New Vision for Progressing Advanced Therapies

Nathaniel Youndt

ReciBioPharm

PAO-10-24-CL-13Oct 25, 2024
Cryoport
Biopharma

Life Sciences and Cryoport Form Partnership to Elevate Standards for Frozen Egg, Embryo, etc Offsite Storage and Biologistics

Cryoport

PR-10-24-NI-52Oct 21, 2024
MOBILion Systems, Inc.
Clinical Development

MOBILion Systems Unveils Novel High Resolution Mass Spectrometry Functionality for Proteomics Workflows

MOBILion Systems, Inc.

PR-10-24-NI-51Oct 21, 2024
MarketsandMarkets™
Financing

mRNA Synthesis & Manufacturing Market to Hit USD 738.3 Million by 2029 with 3.4% CAGR | MarketsandMarkets™

MarketsandMarkets™

PR-10-24-NI-50Oct 17, 2024
Novavax
Clinical Trials

Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial

Novavax

PR-10-24-NI-48Oct 17, 2024
Harbour BioMed
Clinical Trials

Harbour BioMed Announces the Phase I Study Results in Combination with Toripalimab in Advanced Melanoma and Other Solid Tumors

Harbour BioMed

PR-10-24-NI-39Oct 11, 2024
StemCyte
Clinical Trials

StemCyte's HPC Cord Blood Receives RMAT Designation for Long COVID-19 Treatment

StemCyte

PR-09-24-NI-28Oct 07, 2024
Soligenix, Inc.
Clinical Trials

Soligenix Announces Partnership with Sterling Pharma Solutions

Soligenix, Inc.

PR-09-24-NI-32Oct 07, 2024
Cryoport
Cell Therapy

Cryoport launches its IntegriCell™ cryopreservation solution with opening of new facility at its Houston Campus

Cryoport

PR-10-24-NI-35Oct 07, 2024
Thryv Therapeutics Inc
FDA

Thryv Therapeutics Granted FDA Orphan Drug Designation for LQT-1213 in Long QT Syndrome Treatment

Thryv Therapeutics Inc

PR-09-24-NI-27Oct 03, 2024
PTC Therapeutics, Inc.
FDA

PTC Therapeutics Announces FDA Acceptance for Filing of NDA for the Treatment of Pediatric and Adult Phenylketonuria Patients

PTC Therapeutics, Inc.

PR-09-24-NI-26Oct 03, 2024
Agile Cell Supply and Processing to Accelerate Development of the Medicines of the Future
Cell Therapy

Agile Cell Supply and Processing to Accelerate Development of the Medicines of the Future

Justin Irizarry, CFA

OrganaBio

PAO-09-24-CL-11Sep 30, 2024
Johnson & Johnson
Clinical Trail

TALVEY and DARZALEX FASPRO shows deep and durable responses in patients with relapsed or refractory multiple myeloma

Johnson & Johnson

PR-09-24-NI-21Sep 27, 2024
Johnson & Johnson
Clinical Trails

TALVEY and TECVAYLI suggests high response rates in triple-class refractory patients with relapsed or refractory multiple myeloma

Johnson & Johnson

PR-09-24-NI-20Sep 27, 2024
1 / 2